Thermo Fisher Scientific delivered a strong finish to 2025, with Q4 revenue growing 7% year-over-year to $12.21 billion and adjusted EPS increasing 8% to $6.57. For the full year, revenue reached $44.56 billion (up 4%) with adjusted EPS of $22.87 (up 5%), driven by a 2% organic growth rate and a 10 basis point expansion in adjusted operating margin to 22.7%. Performance was bolstered by high single-digit growth in Pharma and Biotech, offsetting softness in Academic/Government and China markets. The company successfully navigated over 100 basis points of tariff and FX headwinds through its PPI business system. Looking ahead, management initiated 2026 guidance for revenue of $46.3-$47.2 billion (4-6% reported) and adjusted EPS of $24.22-$24.80 (6-8% growth), excluding the pending Clario acquisition. Strategic highlights included the $9 billion agreement to acquire Clario, significant M&A activity totaling $13 billion, and continued high-impact innovation across bioproduction and analytical instruments.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | $12.21 Billion | +7% |
| FY 2025 Revenue | $44.56 Billion | +4% |
| Q4 Adjusted EPS | $6.57 | +8% |
| FY 2025 Adjusted EPS | $22.87 | +5% |
| FY 2025 Operating Margin | 22.7% | +10 bps |
| 2026 Revenue Guidance | $46.3 - $47.2 Billion | +4% to +6% |
| 2026 EPS Guidance | $24.22 - $24.80 | +6% to +8% |
Management emphasized the 'Trusted Partner' strategy as a primary driver for share gains, particularly in the Pharma and Biotech end markets. Marc Casper illustrated this with specific anecdotes of executive-level customer engagements where Thermo Fisher facilitated real-time problem solving, deepening relationships beyond transactional vendor status. This strategic focus is critical as it allows TMO to capture 'mid-single-digit plus' growth in their largest market even if industry spending remains flat, leveraging their integrated CDMO/CRO 'Accelerator' solution to lock in long-term contracts.
The company is aggressively deploying capital to bolster its bioproduction and clinical research capabilities. The announcement of the $9 billion Clario acquisition, expected to close in 2026, signals a strategic pivot into high-growth digital endpoint data solutions. Management highlighted that Clario offers a 'double-digit return profile' and immediate accretion ($0.45 EPS), reinforcing a strategy of using M&A to enhance the clinical research offering and capture a larger share of the drug development value chain.
Innovation remains a core pillar, with management detailing a 'spectacular year' of product launches including the Orbitrap Astral Zoom and DynaDrive bioreactor. These high-impact instruments are designed to drive consumables sales and secure long-term revenue streams. The focus on R&D (7% of manufacturing revenue) and collaborations with AI leaders like OpenAI and NVIDIA indicates a strategic intent to integrate advanced technology into their product ecosystem, ensuring they remain the preferred partner for scientific breakthroughs.
Operational discipline via the 'PPI business system' was cited as a key differentiator, enabling margin expansion (+10 bps for FY25) despite over 100 basis points of headwinds from tariffs and FX. This signal suggests that TMO can continue to deliver high-single-digit earnings growth (6-8% guidance for 2026) even in a low organic growth environment (3-4%). The ability to actively manage costs and leverage SG&A (down 40-80 bps) provides a floor for earnings and funds reinvestment in strategic growth areas.
The Academic and Government end market remains a significant weak point, declining low single digits in both Q4 and FY25. Management guided for 'similar conditions' in 2026, specifically citing caution in the US market pending the NIH budget. This creates a risk for the Analytical Instruments segment, which faced pressure in 2025; if government funding remains flat or delayed, the anticipated recovery in this segment could be pushed out, limiting overall organic growth potential.
China continues to present a headwind, with the region declining low single digits in Q4 and mid-single digits for the full year. Management's guidance assumes these conditions persist, which poses a risk to the Asia Pacific growth trajectory. Given the geopolitical complexities and the specific mention of 'tariffs and related FX' causing over 100 bps of margin headwinds, any escalation in trade tensions or a slower-than-expected recovery in China biotech funding could negatively impact the 3-4% organic growth outlook.
The 2026 guidance implies a slow start to the year, with Q1 organic growth expected to be 'a couple of points lower' than the full-year average. This phasing risk is driven by selling days and the timing of pharma services revenue. A weak Q1 could spook investors if the second-half acceleration relies heavily on academic funding recovery or biotech funding lags, which typically take 'six months on average' to translate into spending.
While the Clario acquisition is framed as highly accretive, the integration of a $1.5 billion revenue digital technology business into a traditional life sciences conglomerate carries execution risk. The guidance notes a 7-cent dilution in 2026 from financing costs and integration investments, and while the long-term profile is attractive, the complexity of merging digital platforms with existing clinical trial operations could lead to unforeseen hiccups or cultural clashes.
Overall: Management exhibited a confident and assured demeanor throughout the call, frequently emphasizing the company's resilience and 'outstanding execution' despite a challenging macro environment. They consistently reinforced the strength of their 'PPI business system' and 'proven growth strategy' as mechanisms to navigate headwinds like tariffs and soft academic funding. The tone shifted from defensive regarding external factors to highly assertive when discussing internal controls, share gains, and capital deployment capabilities.
Confidence: HIGH - Management provided specific guidance ranges and detailed the exact impact of headwinds (e.g., 100 bps from tariffs), demonstrating a high degree of visibility and control. They used definitive language regarding their ability to deliver earnings growth ('we're going to deliver great earnings') and expressed strong conviction in their 'Trusted Partner' status driving market share gains.
$46.3 billion to $47.2 billion (4-6% reported growth; 3-4% organic growth)
$24.22 to $24.80 (6-8% growth)
Expansion of 50 basis points
Expected to be a couple of points lower than full year average
Hedging & Uncertainty: Management employed a mix of confident operational language and cautious macro hedging. They were definitive regarding internal capabilities ('We're going to deliver great earnings') but used temporal and conditional hedges when discussing market recovery. Phrases like 'we think it appropriate to start at 3% at the beginning of the year' and 'retire risk as we go and progress higher in the range' suggest they are managing expectations carefully. They also hedged the timing of the academic recovery, stating it 'should create tailwinds' but only 'as the year goes on,' indicating they are not banking on an immediate rebound.
We delivered a strong year capped off by an excellent fourth quarter. - Marc Casper, Chairman, President, and CEO
Our growth strategy is resonating with customers. - Marc Casper, Chairman, President, and CEO
We're assuming market conditions are going to be pretty similar to 2025. - Marc Casper, Chairman, President, and CEO
We're going to deliver great earnings right? And we did a great job of navigating 2025. - Stephen Williamson, Senior Vice President and CFO
The guidance assumes 3% to 4% organic revenue growth... and 50 basis points of adjusted operating margin expansion. - Stephen Williamson, Senior Vice President and CFO
We just wanna set ourselves up... for success this year. - Marc Casper, Chairman, President, and CEO
Analyst Sentiment: Analysts were focused on the sustainability of the growth acceleration and the specific drivers behind the 3-4% organic guide, contrasting it with the 2% achieved in 2025. Questions probed the reality of pharma budget improvements and the specific impact of AI on instrument demand.
Management Responses: Management responses were detailed and anecdotal, using specific customer meeting stories to illustrate their 'Trusted Partner' advantage. They deflected concerns about macro weakness by emphasizing their ability to control what they can (operational execution, share gains) while waiting for macro conditions to normalize.
Discussion on the 'Trusted Partner' strategy and how it is driving share gains in Pharma/Biotech despite flat industry spending.
Inquiry into the impact of AI on wet lab demand, with management asserting that AI leads to more confident research and thus more wet lab experimentation.
Questions regarding the performance of the Analytical Instruments segment and the specific headwinds in the US Academic market.
Clarification on the 2026 guidance framework, specifically the phasing of growth and the exclusion of the Clario acquisition.
Thermo Fisher Scientific remains a premier compounder, demonstrating resilience through its diversified portfolio and operational excellence. The 2026 guidance for 6-8% EPS growth, despite modest organic revenue assumptions, highlights the power of the PPI business system to expand margins and manage through macro headwinds. The strategic pivot into digital clinical research via the Clario acquisition and the consistent share gains in Pharma/Biotech underscore the company's ability to evolve and capture high-value adjacencies. While near-term risks exist in China and Academic funding, TMO's 'Trusted Partner' status and robust capital deployment strategy provide a strong foundation for long-term value creation.
China declined low single digits in Q4 and mid-single digits for the full year. Management assumes similar conditions for 2026, indicating ongoing pressure in this key geography.
The end market declined low single digits. Management expects a 'cautious' environment in 2026 with a 'flat to slightly up NIH budget,' suggesting a delayed recovery in spending.
Management reported 'good confidence' from pharma customers and excitement around pipelines. Biotech funding data shows improvement, though a 6-month lag is expected before spending impacts results.
Tariffs and related FX caused over 100 basis points of headwind in 2025. Guidance assumes current tariffs, with no additional policy changes factored in.